Passage BIO, Inc.
PASG Nasdaq
SEC CIK 1787297
Follow Passage BIO
Weekly email: filings, results, news
Net income
−$7.8M
+16.7% vs same quarter last year
EPS, diluted
−$2.44
+17.6% vs same quarter last year
Operating cash flow
−$9.2M
−45% vs same quarter last year
Operating income
−$8.3M
+20% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$45.5M |
| FY24 | −$64.8M |
| FY23 | −$102.1M |
| FY22 | −$136.1M |
| FY21 | −$185.4M |
| FY20 | −$112.2M |
| FY19 | −$45.6M |
| FY18 | - |
News
No stories filed under Passage BIO yet - coverage appears here as the news feed clusters it.